HERG-IN-3

HERG-IN-3 is an orally active hERG blocker with an IC50 of 44.5 nM. hERG-IN-3 exhibits a Ki for β2-adrenergic receptor of 14 nM. hERG-IN-3 exhibits the skeletal muscle Nav1.4 and sodium channel-blocking activities (IC50 = 4.4 μM, 3-fold increasement than hNav1.5) . hERG-IN-3 displays a potent antimyotonic activity in an animal model. hERG-IN-3 can be used for the study of Myotonia Congenita[1].

Product Specifications

UNSPSC

12352005

Target

Adrenergic Receptor; Potassium Channel; Sodium Channel

Related Pathways

GPCR/G Protein; Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Smiles

OC(COC1=CC=CC(O)=C1)CN2CCC(N(C3=NC4=CC=C(O)C=C4S3)C)CC2

Molecular Formula

C22H27N3O4S

Molecular Weight

429.53

References & Citations

[1]Cavalluzzi MM, et al. Hunting for lubeluzole analogues as antimyotonic agents with reduced cardiac liability. Eur J Med Chem. 2025 Nov 5;297:117964.